Evidence map›Paper›PMID 34908770›Full record

ReviewJournal of cutaneous and aesthetic surgery

Intralesional Agents in Dermatology: Pros and Cons.

Jagdish Sakhiya, Dhruv Sakhiya, Jitesh Kaklotar, Bansi Hirapara, Madhav Purohit, Krishna Bhalala, Feral Daruwala, Nimish Dudhatra

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of cutaneous and aesthetic surgery. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Jagdish SakhiyaSakhiya Skin Clinic, 2nd Floor, Ayush Doctor House, Station-Lal Darwaja Road, Surat, Gujarat, India.
Dhruv SakhiyaB.J. Medical College, New Civil Hospital Asarwa, Ahmedabad, Gujarat, India.
Jitesh KaklotarSakhiya Skin Clinic, 2nd Floor, Ayush Doctor House, Station-Lal Darwaja Road, Surat, Gujarat, India.
Bansi HiraparaSakhiya Skin Clinic, 2nd Floor, Ayush Doctor House, Station-Lal Darwaja Road, Surat, Gujarat, India.
Madhav PurohitSakhiya Skin Clinic, 2nd Floor, Ayush Doctor House, Station-Lal Darwaja Road, Surat, Gujarat, India.
Krishna BhalalaSakhiya Skin Clinic, 2nd Floor, Ayush Doctor House, Station-Lal Darwaja Road, Surat, Gujarat, India.
Feral DaruwalaSakhiya Skin Clinic, 2nd Floor, Ayush Doctor House, Station-Lal Darwaja Road, Surat, Gujarat, India.
Nimish DudhatraSakhiya Skin Clinic, 2nd Floor, Ayush Doctor House, Station-Lal Darwaja Road, Surat, Gujarat, India.
B.J. Medical College · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since introduced in 1961, intralesional (IL) agent has become an essential part of the dermatological practice. The term IL referred to the direct delivery of agent percutaneously into skin lesions. This therapeutic approach is relatively safe, easy to perform and applicable for a broad range of dermatological conditions. On the other hand, immediate side effects, including pain during administration, bleeding, high risk of infection and allergic reaction, and subsequent side effects involving skin changes such as atrophy, telangiectasia, pigmentary changes, and striae are usually associated with this modality. This review paper highlights the pros and cons of IL agents in modern dermatology practice.

Indexed as

5-FluorouracilBecause intralesional agents are relatively safe, easy to implement, and effective in a broad spectrum of dermatological indication with excellent success rate and minimum systemic side effects, the trends in its use have been emerging nowadays. Pros over the cons make it a preferred choice in the dermatology field.bleomycinbotulinum toxin-A and hyaluronic acid fillerscorticosteroidscryotherapyimmunotherapyintralesional agentsmesotherapyplatelet-rich plasma

Identifiers

PMID34908770
PMCPMC8611707
OpenAlexW3205159004

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.